Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/2067/1577
Titolo: | The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses | Autori: | Sartorius, Rossella Pisu, Paola D'Apice, Luciana Pizzella, Luciano Romano, Chiara Cortese, Giancarlo Giorgini, Angela Santoni, Angela De Berardinis, Piergiuseppe Velotti, Francesca Romana |
Parole chiave: | Vaccine;Cytotoxic T lymphocytes;Tumor immunology;Bladder cancer | Data pubblicazione: | 2008 | Editore: | American Association of Immunologists | Fonte: | Sartorius, R. et al. 2008. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. "Journal of Immunology" 180 (6): 3719-3728 | Abstract: | Delivery of tumor-associated antigen (TAA)-derived peptides in a high immunogenic form represents one of the key issues for effective peptide-based cancer vaccine development. Here, we report the ability of non-pathogenic filamentous bacteriophage fd virions to deliver HLA-A2-restricted MAGE-A10254-262- or MAGE-A3271-279-derived peptides and elicit potent specific CTL responses in vitro and in vivo. Interestingly, human anti-MAGE-A3271-279-specific CTLs were able to kill human MAGE-A3+ tumor cells, even if these cells naturally express a low amount of MAGE-A3271-279 peptide-HLA epitope surface complexes and are usually not recognized by CTLs generated by conventional stimulation procedures. MAGE-A3271-279-specific/CD8+ CTL clones were isolated from in vitro cultures and their high avidity for antigen recognition was assessed. Moreover, in vivo tumor protection assay showed that vaccination of humanized HHD (HLA-A2.1+/H2-Db+) transgenic mice with phage particles expressing MAGE-A3271-279-derived peptides hampered tumor growth. Overall, these data indicate that engineered filamentous bacteriophage virions increase substantially the immunogenicity of delivered TAA-derived peptides, thus representing a novel powerful system for the development of effective peptide-based cancer vaccines. |
Acknowledgments: | L'articolo è disponibile sul sito dell'editore http://www.jimmunol.org |
URI: | http://hdl.handle.net/2067/1577 | ISSN: | 0022-1767 |
È visualizzato nelle collezioni: | DECOS - Archivio della produzione scientifica |
File in questo documento:
File | Descrizione | Dimensioni | Formato | |
---|---|---|---|---|
JImmunology1577.pdf | 111.56 kB | Adobe PDF | Visualizza/apri |
Page view(s)
195
Last Week
0
0
Last month
4
4
controllato il 27-mar-2024
Download(s)
108
controllato il 27-mar-2024
Google ScholarTM
Check
Tutti i documenti nella community "Unitus Open Access" sono pubblicati ad accesso aperto.
Tutti i documenti nella community Prodotti della Ricerca" sono ad accesso riservato salvo diversa indicazione per alcuni documenti specifici